Dolutegravir Monotherapy Versus Dolutegravir/Abacavir/Lamivudine for Virologically Suppressed People Living With Chronic Human Immunodeficiency Virus Infection: The Randomized Noninferiority MONotherapy of TiviCAY Trial.

doi:10.1093/cid/ciy1132

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Dolutegravir Monotherapy Versus Dolutegravir/Abacavir/Lamivudine for Virologically Suppressed People Living With Chronic Human Immunodeficiency Virus Infection: The Randomized Noninferiority MONotherapy of TiviCAY Trial.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - 15 Oct 2019

Hocqueloux Laurent, Raffi François, Prazuck Thierry, Bernard Louis, Sunder Simon, Esnault Jean-Luc, Rey David, Le Moal Gwenaël, Roncato-Saberan Mariam, André Marie, Billaud Eric, Valéry Antoine, Avettand-Fènoël Véronique, Parienti Jean-Jacques, Allavena Clotilde

Abstract excerpt

BACKGROUND: We investigated whether dolutegravir (DTG) monotherapy could be used to maintain virological suppression in people living with human immunodeficiency virus (HIV) on a successful dolutegravir-based triple therapy. METHODS: MONCAY (MONotherapy of TiviCAY) was a 48-week, multicentric, randomized, open-label, 12% noninferiority margin trial. Patients with CD4 nadir >100/μL, plasma HIV-1 RNA <50 copies/mL...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-HIV Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Confidence Intervals

Share to Dideoxynucleosides

Share to Heterocyclic Compounds, 3-Ring

Source

Open in PubMed

Identifiers

PMID: 30601976
DOI: 10.1093/cid/ciy1132

Genes

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dolutegravir Monotherapy Versus Dolutegravir/Abacavir/Lamivudine for Virologically Suppressed People Living With Chronic Human Immunodeficiency Virus Infection: The Randomized Noninferiority MONotherapy of TiviCAY Trial.PMID 30601976Read ↗

Dolutegravir-based maintenance monotherapy versus dual therapy with lamivudine: a planned 24 week analysis of the DOLAM randomized clinical trial.Semantic proximity Read ↗

Virologic failure and HIV drug resistance on simplified, dolutegravir-based maintenance therapy: Systematic review and meta-analysisSemantic proximity Read ↗

Prevalence of Emergent Dolutegravir Resistance Mutations in People Living with HIV: A Rapid Scoping Review.Semantic proximity Read ↗

Dolutegravir versus placebo in subjects harbouring HIV-1 with integrase inhibitor resistance associated substitutions: 48-week results from VIKING-4, a randomized study.Semantic proximity Read ↗

Dolutegravir plus lamivudine for the treatment of HIV-1 infection.Semantic proximity Read ↗

Abacavir/dolutegravir/lamivudine single-tablet regimen: a review of its use in HIV-1 infection.Semantic proximity Read ↗

Doing More With Less: Review of Dolutegravir-Lamivudine, a Novel Single-Tablet Regimen for Antiretroviral-Naïve Adults With HIV-1 Infection.Semantic proximity Read ↗

Dolutegravir-based monotherapy or dual therapy maintains a high proportion of viral suppression even in highly experienced HIV-1-infected patients.Semantic proximity Read ↗

Effect of dolutegravir in combination with Nucleoside Reverse Transcriptase Inhibitors (NRTIs) on people living with HIV who have pre-existing NRTI mutations.Semantic proximity Read ↗

Risk of Emergent Dolutegravir Resistance Mutations In People Living With HIV: A Rapid Scoping ReviewSemantic proximity Read ↗

Dolutegravir, the Second-Generation of Integrase Strand Transfer Inhibitors (INSTIs) for the Treatment of HIVSemantic proximity Read ↗

Dolutegravir plus lamivudine for initial treatment of HIV-1-infected participants with HIV-1 RNA <500 000 copies/mL: week 48 outcomes from ACTG 5353.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.